This message was sent to ##Email##
|
|
|
|
|
Register today for the 2016 Fall Forum being held November 10-11, 2016 at the Mandalay Bay/Delano Resort in Las Vegas. Click here to visit the conference website.
Scientific American
Carl Zimmer writes: I know it sounds strange, but I feel very grateful to a database. It saved me from a lifelong fear of dropping dead of a heart attack.
The database is known as ExAC, and I had my first experience with it after I got my genome sequenced. For a few weeks, I brought it from one lab to another to ask scientists to help me make sense of it.
Their analysis brought up a doozy of a finding. I have a variant in a gene for heart muscles, called DSG2.
READ MORE
HealthDay News via CBS News
The activity of two genes may help predict certain breast cancer patients’ chances of survival and guide their treatment, British researchers report.
“We have seen major strides in the treatment of breast cancer, but once it begins to spread round the body it is still often fatal,” said Paul Workman. He is chief executive of the Institute of Cancer Research (ICR) in London, which conducted the research.
READ MORE
|
Promoted by
|
|
|
|
 |
Medical Xpress
Recent research has suggested that academic performance, reading ability and IQ have a genetic basis. This reinforces the popular notion that intelligence and related cognitive capacities are somehow "in our genes."
This has led some people to reject the importance of educational interventions on the grounds that spending money on nurture isn't going to significantly affect the abilities nature has given us.
READ MORE
Bloomberg
Of all living things, why do humans alone create advanced technology? Not long ago, scientists thought it was because we are the only intelligent life form on this planet. That explanation alone no longer suffices. Over the last decade, scientists have discovered that crows can use tools, hyenas can cooperate to solve complex problems, jays can plan for the future, rats and voles can demonstrate empathy, and ducklings are capable of abstract thought.
READ MORE
Health Information Designs
Spending on specialty pharmaceuticals climbed 18 percent in 2015, compared to an increase of less than 1 percent for standard prescription medications. Despite their effectiveness, specialty medications are under constant scrutiny—reflecting the growing concern of balancing clinical innovation with responsible spending.
READ MORE
LiveScience
Cancer has passed heart disease as the leading cause of death in nearly half of U.S. states, according to a new report.
In 2014, cancer was the leading cause of death in 22 states, including many in the West and Northeast. That's a jump from the year 2000, when cancer was the leading cause of death in just two states. In the rest of the 28 states, heart disease remained the leading cause of death in 2014.
READ MORE
HealthDay News via Chicago Tribune
Diagnoses of early prostate cancer continue to decline in the United States, following the U.S. Preventive Services Task Force recommendation against routine screening for the disease, researchers report.
The screening involves a blood test that identifies levels of PSA, a protein produced by the prostate gland. That test can determine when cancer exists, but it often wrongly identifies nonexistent cancer.
READ MORE
The New York Times
Carcinogens abounded 1.7 million years ago in Early Pleistocene times when a nameless protohuman wandered the South African countryside in what came to be known as the Cradle of Humankind.
Then, as now, ultraviolet radiation poured from the sun, and radon seeped from granite as it decayed in the ground. Viruses like ones today scrambled DNA. And there were the body’s own carcinogens, hormones that switch on at certain times of life, accelerating the multiplication of cells and increasing the likelihood of mutations.
READ MORE
| | BIOTECH/DIAGNOSTICS/PERSONALIZED MEDICINE |
Health IT Analytics
Imaging analytics are an untapped resource of big data that will lead the way towards personalized medicine and predictive, tailored care.
Across the healthcare industry, there is a rising demand for personalized medicine, including the desire to have better access, visibility and insight into patient records.
READ MORE
 |
|
Genoptix, a Novartis company, is a leading CAP-accredited and CLIA-certified specialized laboratory focused on delivering diagnostic services to hematology/oncology patients and the physicians who treat them.
800.755.1605 / www.genoptix.com MORE
|
|
| | EMERGING MEDICAL TECHNOLOGIES |
Fast Company
Apple's ambitions in the health sector continue to expand, with its digital health team making its first known acquisition — personal health data startup Gliimpse, Fast Company has learned.
Silicon Valley-based Gliimpse has built a personal health data platform that enables any American to collect, personalize and share a picture of their health data.
READ MORE
Medscape
Can technology be utilized to improve health equity? According to the Pew Research Center, 91-94 percent of all Americans — African American, Latino, and white persons — own a cellphone. When looking at educational levels, 86-88 percent of those who have not attained a high school education own a cellphone.
READ MORE
Los Angeles Times
Visitors to the website of StemGenex, a La Jolla medical group, could be forgiven for thinking that the answer to their prayers is finally at hand. Pitched at sufferers of lung disease, Parkinson’s, autoimmune conditions such as multiple sclerosis and rheumatoid arthritis and even Alzheimer’s, the site offers treatments based on injecting patients with stem cells drawn from their own body fat.
READ MORE
Medical News Today
When a person has a stroke, blood flow to the brain is interrupted, causing brain cells to die within minutes due to lack of oxygen. In some cases, this can result in paralysis, speech and language problems, vision problems, and memory loss. But in a new study, researchers have shown that stem cell therapy increases nerve cell production in mice with brain damage due to stroke.
READ MORE
Forbes
Each year the Pan-Mass Challenge unites roughly six-thousand cyclists, volunteers, donors and sponsors who share a passion for discovering improved cures for all types of cancer. All money raised by the PMC is donated to the Dana-Farber Cancer Institute.
The riders who partake in the PMC are committed. To participate, you must pay a $250 registration fee and raise a minimum of $4,700 for Dana-Farber.
READ MORE
| | ACCOUNTABLE CARE ORGANIZATIONS |
Health Data Management
Accountable care organizations are gaining prominence as one of the nation’s leading approaches for making the shift to value-based care. Providers in these ACOs are facing a variety of business challenges, including gathering and using data to improve care.
In many cases, ACOs are finding they need to incorporate data from a variety of sources, placing new importance on activities such as master data management, analytics and population health management applications.
READ MORE
FierceHealthcare
The accountable care organization model has had its share of ups and downs, and two viewpoints published in the Journal of the American Medical Association are divided on whether they are truly successful.
The model is still in its infancy, and that completely discounting it would be a mistake, as ACOs show signs of promise as a payment and delivery model, write Zirui Song, M.D., a resident in the Department of Medicine at Massachusetts General Hospital in Boston, and Elliot S. Fisher, M.D., director of the Dartmouth Institute for Health Policy and Clinical Practice.
READ MORE
| | FDA: NEW TREATMENTS AND TECHNOLOGY |
Forbes
Rita Rubin writes: This week marked one year since the Food and Drug Administration approved the controversial drug Addyi, dubbed the “female Viagra” because both medications are supposed to improve users’ sex lives.
I’ve been covering health long enough to have written about Viagra on the first anniversary of its March 1998 approval. I know Viagra, and I can tell you, as far as sales and celebrity, not to mention how it works, Addyi is no Viagra.
READ MORE
Medscape
The U.S. Food and Drug Administration has approved an oral, abuse-deterrent, extended-release formulation of oxycodone hydrochloride and naltrexone hydrochloride (Troxyca ER) for severe pain when other treatment options are not successful or tolerated, according to an announcement from Pfizer.
The capsules, previously known as ALO-02, consist of an ER oxycodone "pellet" that surrounds a naltrexone core. If the medication is crushed, the naltrexone can counteract the oxycodone's effects.
READ MORE
The Wall Street Journal
A column by Greg Ip presented a summary of problems with the Affordable Care Act stemming from its major, popular feature: prohibiting insurers from discriminating in enrollment or premiums based on an individual’s pre-existing health conditions.
The 2010 healthcare law, Ip writes, is suffering the same slow “unraveling” of the health insurance market it was designed to fix: attracting disproportionate numbers of older, sicker patients, whose healthcare costs drive up premiums, which in turn prompts younger, healthier customers to drop the insurance (even with subsidies) or to opt out of enrolling (and choosing to pay a modest “tax” penalty).
READ MORE
|
Merrimack Announces Inclusion of ONIVYDE(R) (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma. Please click here to view the entire press release.
|
| We wanted you to be aware that the FDA has approved a new indication for IBRANCE (palbociclib) 125mg capsules. Click here to read the press release. |
Check out JMCM’s new website at www.jmcmpub.org
|
| Seattle Genetics Announces FDA Regular Approval of ADCETRIS® for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression. Click here to view more information. |
| Sandoz, a Novartis company, announced today that Zarxio(TM) (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the US. Please click here for more information.
. |
|
Missed last week's issue? See which articles your colleagues read most.
|
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
 |
|
| We are an independent, objective clinical services company dedicated to providing solutions that focus on maximizing quality of care while limiting financial or regulatory risk.
|
|
|
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
